Medical Information Notice: This article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified clinician for your personal situation.

Pancreatic cancer is one of the most aggressive malignancies, often diagnosed at advanced stages due to vague early symptoms. It has the lowest survival rate among common cancers. Here’s a detailed yet concise overview:

  • Types
    • Pancreatic Ductal Adenocarcinoma (PDAC)
      • 90–95% of cases. Arises from exocrine gland cells lining the pancreatic ducts.
      • Highly aggressive, resistant to treatment.
    • Pancreatic Neuroendocrine Tumors (PNETs)
      • 3–5%. Develop from hormone-producing cells (e.g., insulinomas, gastrinomas).
      • Often slower-growing; better prognosis than PDAC.
    • Rare Types: Acinar cell carcinoma, pancreatoblastoma.
  • Symptoms
    • Early: Often absent or nonspecific (indigestion, vague abdominal discomfort).
    • Classic Triad (Advanced Disease):
      • Painless jaundice (yellow skin/eyes, dark urine, itching) – if tumor in the pancreatic head.
      • Unexplained weight loss (>10% body weight).
      • Epigastric or back pain (dull, persistent; worse when lying down).
    • Other Signs:
      • New-onset diabetes, light-colored stools, loss of appetite, thrombophlebitis (migratory blood clots).
  • Risk Factors
    • Age: >90% occur in adults >55 yrs; peak at 65–75 yrs.
    • Smoking: ↑ Risk 2–3×.
    • Chronic Pancreatitis: Long-term inflammation (especially hereditary).
    • Diabetes: New-onset diabetes in adults may be an early sign.
    • Obesity & Diet: High-fat, processed meat consumption.
    • Genetics:
      • Inherited Syndromes: BRCA2, PALB2, Lynch syndrome, Peutz-Jeghers, FAMMM (melanoma).
      • Family History: 5–10% have a familial link.
  • Diagnosis
    • Imaging:
      • CT with Pancreatic Protocol (Triple-Phase): Gold standard for detection/staging.
      • MRI/MRCP: Evaluates ductal structures; useful for small tumors.
      • Endoscopic Ultrasound (EUS): Combines scope/ultrasound; allows biopsy.
    • Biopsy:
      • Via EUS or CT-guided needle, confirms diagnosis.
    • Tumor Markers:
      • CA 19-9: Elevated in 80% of PDAC (but not specific; used for monitoring).
    • Genetic Testing:
      • Recommended for all patients (guides therapy, especially if BRCA or Lynch-related).
  • Treatment: Treatment depends on stage, location, and patient fitness.
    • Resectable Tumors (15–20% of cases):
      • Surgery:
        • Whipple Procedure (Pancreaticoduodenectomy): For head tumors.
        • Distal Pancreatectomy: For body/tail tumors.
      • Adjuvant Therapy:
        • Chemo (FOLFIRINOX or gemcitabine/capecitabine) post-surgery to reduce recurrence.
    • Locally Advanced (Unresectable):
      • Chemoradiation: FOLFIRINOX or gemcitabine-based chemo ± radiation.
      • Borderline Resectable: Neoadjuvant chemo → reassessment for surgery.
    • Metastatic (Stage IV):
      • Chemotherapy:
        • 1st-line: FOLFIRINOX (fit patients) or gemcitabine + nab-paclitaxel.
        • 2nd-line: Nanoliposomal irinotecan + 5-FU or modified FOLFOX.
      • Targeted Therapy:
        • Olaparib (PARP inhibitor) for BRCA-mutated PDAC.
        • Larotrectinib/entrectinib for NTRK fusion-positive tumors.
      • Immunotherapy: Only for MSI-H/dMMR tumors (pembrolizumab).
  • Prognosis & Key Factors
    • Overall, 5-Year Survival: ~11% (improving slowly with new therapies).
    • Favorable Factors:
      • Early stage, surgical resection, PNET subtype, good response to chemo.
    • Poor Prognosis:
      • Metastasis, high CA 19-9, weight loss, poor performance status.
  • Prevention & Early Detection
    • High-Risk Groups (e.g., BRCA carriers, familial PC):
      • Surveillance with annual MRI/EUS + CA 19-9.
    • Lifestyle:
      • Smoking cessation, weight control, and limited alcohol.
    • Diabetes Management: New-onset diabetes warrants pancreatic evaluation.
    • Rapid Decline: Often requires early hospice involvement.

Multidisciplinary care (surgery, oncology, GI, palliative care) is essential.

Frequently Asked Questions (FAQ)

Q1: Why is pancreatic cancer so difficult to detect early?
The pancreas is located deep in the abdomen, and early-stage tumors cause no specific symptoms. The vague early signs — indigestion, mild back discomfort, and fatigue — are easily attributed to other causes. By the time classic symptoms like painless jaundice or significant weight loss appear, the cancer is often already locally advanced or metastatic.

Q2: What is the Whipple procedure?
The Whipple procedure (pancreaticoduodenectomy) is a complex surgery that removes the head of the pancreas, the duodenum, part of the bile duct, the gallbladder, and sometimes part of the stomach. It is the standard surgical approach for tumors located in the head of the pancreas and offers the best chance for cure in resectable cases. Only about 15–20% of patients are eligible for this surgery at diagnosis.

Q3: What is painless jaundice and why is it a red flag?
Painless jaundice — yellowing of the skin and eyes — occurs when a pancreatic head tumor blocks the bile duct, preventing bile from draining normally. The absence of pain distinguishes it from other causes of jaundice and is an important clue that warrants urgent medical evaluation. It is one of the classic presentations of pancreatic cancer.

Q4: What is FOLFIRINOX and when is it used?
FOLFIRINOX is a combination chemotherapy regimen consisting of four drugs: leucovorin, fluorouracil (5-FU), irinotecan, and oxaliplatin. It is the preferred first-line chemotherapy for fit patients with metastatic or locally advanced pancreatic ductal adenocarcinoma (PDAC), offering better outcomes than older single-agent regimens, though with more side effects.

Q5: Does diabetes increase the risk of pancreatic cancer?
There is a complex relationship between the two. Chronic or long-standing type 2 diabetes is a modest risk factor for pancreatic cancer. More importantly, new-onset diabetes in adults over 50, especially when accompanied by weight loss, can sometimes be an early sign of an underlying pancreatic tumor. Such presentations warrant prompt evaluation.

Q6: Who is at hereditary risk for pancreatic cancer?
Approximately 5–10% of pancreatic cancers are linked to inherited mutations. These include BRCA2, PALB2, Lynch syndrome, Peutz-Jeghers syndrome, and familial atypical multiple mole melanoma (FAMMM). High-risk individuals may be eligible for surveillance with annual MRI and/or endoscopic ultrasound (EUS) at specialized centers.

Q7: What is the overall prognosis for pancreatic cancer?
Pancreatic cancer has the lowest 5-year survival rate among common cancers, at approximately 11% overall. However, outcomes vary greatly by stage: patients who undergo successful surgical resection have a 5-year survival of 15–25%, while those with metastatic disease have median survival measured in months. Newer chemotherapy combinations and targeted therapies are gradually improving outcomes.

Medical Disclaimer

MediPulse publishes this content for patient education. It may not reflect the latest guideline changes in every jurisdiction. Do not delay seeking care because of something you read here.